Extra treatment with glofitamab after first therapy for aggressive lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of large B-cell lymphoma that is considered high-risk.
- You've completed your first treatment (chemotherapy with rituximab) and it worked well (you are in remission or very close to it).
- You have not had a stem cell transplant (within 100 days) or CAR-T therapy (within 30 days) before this trial.
- You have no serious heart conditions, active brain or nervous system disorders, or other cancers in the last 5 years.
- You agree to use effective contraception (if applicable) during the trial and for 2 years after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a medicine called glofitamab works and how safe it is for people with a type of blood cancer (diffuse large B-cell lymphoma) that did not respond to first treatment or came back within a year. If you qualify, you may receive glofitamab as part of your care, and the study will track your progress.
This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
This trial combines a targeted antibody treatment called glofitamab with radiation therapy for people whose diffuse large B-cell lymphoma has come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
Hear when a new B Cell Lymphoma (BCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.